Just looking back to last 2 presentations on Anisina both available on Novogen website:
DESIGN, SYNTHESIS AND SAR OF SOME FIRST-IN-CLASS CYTOSKELETON TARGETING SUBSTITUTED INDOLES IN CLINICAL DEVELOPMENT FOR A VARIETY OF CANCERS
Dr Eleanor Eiffe Drug Discovery Program Manager Novogen
IN VIVO ACTIVITY
When you look at the combined activity of 150mg/kg of Anisina combined with 0.5mg/kg of VCR (Vincristine) you can see on figure A that using Vincrisitine alone saw the tumor grow over the 18 days from just over 300mm3 to just over 900mm3 or a tripling. When used in combination with Anisina the tumor decreased over the 18 days from 300mm3 to around 200mm3... or a 1/3 reduction compared to a tripling..
When you look at figure B you can see the survival rate again with using Vincristine alone (all dead at around 40days) to when used in combination with Anisina - 40% survival at 50 days & 20% survival well past 100 days..
The thing that is also interesting to work out is if they're able to increase the dosage of Anisina in the clinic to above 150mg/kg and possibly decrease the more toxic Vincristine and still have a better outcome ie. better for children.. the data on the toxicology may well be the heads up with whats expected to translate in the clinic (fingers & toes crossed)
